Condition
Refractory Cancer Pain
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Early P 1 (1)
P 2 (1)
Trial Status
Completed1
Unknown1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07489625Early Phase 1Not Yet RecruitingPrimary
Hydromorphone With Electroacupuncture and Ear Acupoint Pressing for Refractory Cancer Pain
NCT03362073Phase 2Unknown
Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients
NCT04491123CompletedPrimary
Intrathecal Analgesia Effects on Cancer Patients Discomfort Symptoms
Showing all 3 trials